Emergency planned re-infusion therapy and hospitalisation for community-acquired pneumonia: a retrospective case-control study

被引:0
|
作者
Chen, Sheng-Xian [1 ]
Yang, Zhi-Kai [1 ]
Lin, Lin [2 ]
Liao, Hou-Zhen [1 ]
Xiang, Xiao-Ting [1 ]
Liu, Di [1 ]
Huang, Jian-Shan [1 ]
机构
[1] Xiamen Chang Gung Hosp, Dept Emergency Clin, 123 Xiafei Rd, Xiamen, Fujian, Peoples R China
[2] Xiamen Chang Gung Hosp, Dept Gen Med, Xiamen, Peoples R China
关键词
LOW-RISK PATIENTS; LEVOFLOXACIN; GUIDELINES; MANAGEMENT; SEVERITY; ADULTS;
D O I
10.7189/jogh.15.04044
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Community-acquired pneumonia (CAP) is a frequent reason for emergency department visits and leads to increased direct medical costs, particularly due to hospitalisation. This study aims to examine the differences between emergency planned re-infusion therapy and hospitalisation in patients with CAP. Methods This retrospective case-control study involved 1889 CAP patients treated at the Emergency Internal Medicine Department of Class A tertiary Hospital in China from 1 January 2020 to 31 December 2022. Patients were divided into groups receiving either emergency planned re-infusion therapy or hospitalisation. Independent sample t tests and chi 2 tests were used to compare the clinical outcomes and economic impacts between the two groups across different pneumonia severity index (PSI) classifications.<br /> Results The study enrolled 1889 CAP patients. For PSI I-II patients, the improvement rates were 99.51% in the emergency planned re-infusion therapy group and 99.69% in the hospitalisation group, showing no statistically significant difference (P> 0.05). Similarly, no significant difference was observed for PSI III patients (84.16 vs. 89.82%). However, significant differences emerged for PSI IV patients, with improvement rates of 50% in the emergency planned re-infusion therapy group and 90.59% in the hospitalisation group (P < 0.001). Statistically significant differences were also noted in treatment duration (5.13 +/- 1.65 days vs. 7.60 +/- 3.93 days, P < 0.001) and total treatment costs (1921.57 Chinese Yuan (CNY) +/- 923.16 vs. 9083.80 CNY +/- 3583.55, P<0.001) between the two groups.<br /> Conclusions Emergency planned re-infusion therapy for CAP is an effective and cost-efficient alternative that can reduce both treatment duration and costs, particularly for patients with PSI I-III. It is recommended that emergency physicians give priority to emergency re-infusion therapy for patients with PSI I-III. In addition, it is recommended that hospitals strengthen the classification and treatment training programmes for emergency department physicians to recognise the patients with PSI I-IV.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study
    Cilloniz, Catia
    Miguel-Escuder, Lucia
    Luisa Pedro-Bonet, Maria
    Falco, Vicenc
    Lopez, Yessica
    Garcia-Vidal, Carolina
    Gabarrus, Albert
    Moreno, Asuncion
    Torres, Antoni
    Miro, Jose M.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (06) : 958 - 961
  • [42] Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study
    Campos, Catia Cilloniz
    Torres, Antoni
    Manzardo, Christian
    Gabarrus, Albert
    Ambrosioni, Juan
    Garcia, Felipe
    Ceccato, Adrian
    Mensa, Josep
    Casa, Jorge Puig de la Bella
    Moreno, Asuncion
    Miro, Jose Maria
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [43] Predicting treatment failure in patients with community acquired pneumonia: a case-control study
    Martin-Loeches, Ignacio
    Valles, Xavier
    Menendez, Rosario
    Sibila, Oriol
    Montull, Beatriz
    Cilloniz, Catia
    Artigas, Antonio
    Torres, Antoni
    RESPIRATORY RESEARCH, 2014, 15
  • [44] Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study
    Kang, C. -I.
    Song, J. -H.
    Kim, S. H.
    Chung, D. R.
    Peck, K. R.
    So, T. M.
    Hsueh, P. -R.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (01) : 55 - 59
  • [45] Risk factors for community-acquired pneumonia among adults in Kenya: a case–control study
    Esther Muthumbi
    Brett S. Lowe
    Cyprian Muyodi
    Esther Getambu
    Fergus Gleeson
    J. Anthony G. Scott
    Pneumonia, 9 (1)
  • [46] Incidence of community-acquired pneumonia hospitalisation in persons with bronchiectasis during the COVID-19 lockdown in Denmark: a retrospective cohort study
    Romer, Valdemar
    Fosgaard, Martina Bjorka
    Sivapalan, Pradeesh
    Eklof, Josefin
    Saeed, Mohamad Isam
    Toennesen, Louise Lindhardt
    Jordan, Alexander Svorre
    Gissel, Tina
    Johansson, Sofie Lock
    Jensen, Jens-Ulrik Staehr
    BMJ OPEN RESPIRATORY RESEARCH, 2023, 10 (01)
  • [47] A retrospective case series of 44 patients with community-acquired Staphylococcus aureus pneumonia
    Bowles, Darren d
    Perrin, Kyle
    NEW ZEALAND MEDICAL JOURNAL, 2014, 127 (1391) : 75 - 83
  • [48] A case-control study of community-acquired Acinetobacter baumannii pneumonia and melioidosis pneumonia in northeast Thailand: an emerging fatal disease with unique clinical features
    Patamatamkul, Samadhi
    Klungboonkrong, Voravan
    Praisarnti, Pakawas
    Jirakiat, Kittitouch
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 87 (01) : 79 - 86
  • [49] Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections in Acutely Ill Children: A Retrospective Case-Control Study
    Saptharishi Lalgudi Ganesan
    Ankit Mehta
    Keshavmurthy Lakshmikantha
    Muralidharan Jayashree
    Vikas Gautam
    Pallab Ray
    The Indian Journal of Pediatrics, 2021, 88 : 141 - 146
  • [50] Aetiology and therapy of community-acquired pneumonia: a hospital study in northern Italy
    L. Guglielmo
    R. Leone
    European Journal of Clinical Pharmacology, 1997, 51 : 437 - 443